GlassScriptPhysician profile
Brooke Alexandra Hunter
NPI 1790446045
$1,829.05
in general payments reported to CMS, 2019-2025
24 companies · $751 in 2025
The $751 reported for 2025 was more than what 78% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $282 · 2024: $796 · 2025: $751.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,829.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,829.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $254.59 | 2024-2025 | |
| Pfizer INC. | $238.61 | 2023-2025 | |
| Lilly USA, LLC | $208.06 | 2023-2025 | Jardiance, Zepbound, Mounjaro |
| Novartis Pharmaceuticals Corporation | $173.89 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $111.96 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.65 | 2023-2024 | Jardiance |
| Novo Nordisk INC | $94.56 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $91.29 | 2024-2025 | Repatha, Otezla, Repatha |
| Lundbeck LLC | $63.25 | 2023-2025 | Rexulti |
| Xeris Pharmaceuticals, INC. | $59.10 | 2025 | Recorlev, Keveyis |
| Bayer Healthcare Pharmaceuticals INC. | $45.68 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $45.28 | 2025 | Voquezna |
| Glaxosmithkline, LLC. | $42.32 | 2024 | Bexsero, Arexvy, Shingrix |
| Viiv Healthcare Company | $41.34 | 2024-2025 | Apretude |
| Astellas Pharma US INC | $33.59 | 2024 | Veozah |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $31.90 | 2024 | Evkeeza |
| Antares Pharma, INC. | $30.43 | 2025 | Xyosted |
| Inspire Medical Systems, INC. | $26.73 | 2025 | Inspire |
| Genzyme Corporation | $25.02 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.95 | 2025 | Caplyta |
| Ardelyx, INC. | $21.05 | 2024 | Ibsrela |
| Janssen Pharmaceuticals, INC | $20.88 | 2023 | Xarelto |
| Merck Sharp & Dohme LLC | $20.87 | 2024 | Vaxneuvance, Gardasil, Capvaxive |
| Exact Sciences Corporation | $15.05 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Hunter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.